異なる用量の薬NNC0487-0111が2型糖尿病患者の血糖値をどの程度下げるかを比較した研究研究
2型糖尿病の参加者における週1回皮下および1日1回経口NNC0487-0111の安全性と有効性 - 用量設定研究
The study will look at how well different doses of a new medicine called NNC0487-0111 help lower the blood sugar and body weight in people with type 2 diabetes. NNC0487-0111 is a new medicine which cannot be prescribed by doctors but has previously been tested in humans. Participants will either get NNC0487-0111, which is given as tablets or as injections, or placebo. Which treatment the participant get is decided by chance.The study will last for about 43 weeks.
調査の概要
状態
条件
研究の種類
入学 (実際)
段階
- フェーズ2
連絡先と場所
研究場所
-
-
Alabama
-
Birmingham、Alabama、アメリカ、35294
- Uni of Alabama at Birmingham
-
-
California
-
Los Angeles、California、アメリカ、90057
- Velocity Clin Research LA
-
Santa Ana、California、アメリカ、92701
- Southern Cal Clinical Research
-
-
Connecticut
-
Waterbury、Connecticut、アメリカ、06708
- Chase Medical Research LLC
-
-
Florida
-
Fleming Island、Florida、アメリカ、32003
- Fleming Island Ctr for Clin Res
-
Hollywood、Florida、アメリカ、33024
- Encore Medical Research LLC
-
Miramar、Florida、アメリカ、33027
- South Broward Research LLC
-
Orlando、Florida、アメリカ、32825
- Florida Inst For Clin Res
-
Orlando、Florida、アメリカ、32825
- Florida Institute for Clinical research
-
-
Illinois
-
Chicago、Illinois、アメリカ、60607
- Cedar-Crosse Research Center
-
-
Kansas
-
Topeka、Kansas、アメリカ、66606
- Cotton O'Neil Clinical Research Center
-
-
Kentucky
-
Paducah、Kentucky、アメリカ、42001
- Advanced Internal Medicine, PLLC
-
-
Maryland
-
Hyattsville、Maryland、アメリカ、20782
- Medstar Research Institute_Hyattsville
-
Oxon Hill、Maryland、アメリカ、20745
- MD Medical Research
-
-
Massachusetts
-
Boston、Massachusetts、アメリカ、02115
- Brigham & Women's Hospital
-
Methuen、Massachusetts、アメリカ、01844
- ActivMed Practice & Research LLC
-
-
Michigan
-
Troy、Michigan、アメリカ、48098
- Arcturus Healthcare, PLC
-
Troy、Michigan、アメリカ、48098
- Arcturus HC PLC Troy Med Res
-
-
Missouri
-
Chesterfield、Missouri、アメリカ、63005
- Clinical Research Professionals
-
City of Saint Peters、Missouri、アメリカ、63303
- StudyMetrix Research LLC
-
-
New York
-
Albany、New York、アメリカ、12203
- AMC Community Endocrinology
-
-
North Carolina
-
Morehead City、North Carolina、アメリカ、28557
- Centricity Rsrch MHCity Multi
-
Statesville、North Carolina、アメリカ、28625
- Piedmont Healthcare/Research
-
-
North Dakota
-
Fargo、North Dakota、アメリカ、58104
- Lillestol Research LLC
-
Fargo、North Dakota、アメリカ、58104
- Plains Clinical Research Center, LLC_Fargo
-
-
Oklahoma
-
Norman、Oklahoma、アメリカ、73069
- Alliance for Multispec Res
-
-
Pennsylvania
-
Philadelphia、Pennsylvania、アメリカ、19107-6810
- Jefferson Endocrinology Assocs
-
Pittsburgh、Pennsylvania、アメリカ、15236
- Preferred Primary Care Physicians_Pittsburgh
-
-
South Dakota
-
Rapid City、South Dakota、アメリカ、57702
- Health Concepts
-
-
Tennessee
-
Kingsport、Tennessee、アメリカ、37660
- Holston Medical Group
-
Nashville、Tennessee、アメリカ、37203
- Clinical Research Associates
-
Nashville、Tennessee、アメリカ、37203
- MidState Endocrine Associates
-
-
Texas
-
Dallas、Texas、アメリカ、75230
- Velocity Clinical Res-Dallas
-
Houston、Texas、アメリカ、77024
- Victorium Clinical Research
-
Houston、Texas、アメリカ、77079
- PlanIt Research, PLLC
-
Houston、Texas、アメリカ、77061
- Synergy Groups Medical
-
Lampasas、Texas、アメリカ、76550
- Radiance Clinical Research
-
McKinney、Texas、アメリカ、75069
- Tekton Research
-
Waco、Texas、アメリカ、76708
- Hillcrest Family Health Center
-
-
-
-
-
Athens、ギリシャ、115 25
- Iatriko Psychicou Private Clinic
-
Athens、ギリシャ、12462
- U.G.H of Athens "Attikon"
-
Goudi/Athens、ギリシャ、11527
- "Laiko" General Hospital of Athens
-
Thessaloniki、ギリシャ、GR-54643
- EUROMEDICA Gen Clinic The/ki, Endocrin,Metabolism,Diabetes
-
Thessaloniki、ギリシャ、GR-57001
- "Thermi" Private Hosital
-
Thessaloniki、ギリシャ、564 29
- 424 Military General Training Hospital
-
Thessaloniki、ギリシャ、57001
- "Thermi" Private Hosital
-
Thessaloniki、ギリシャ、54645
- EUROMEDICA Gen Clinic The/ki, Endocrin,Metabolism,Diabetes
-
Thessaloniki、ギリシャ、564 29
- 424 Military General Training Hospital - 2nd Department of Internal Medicine
-
-
-
-
-
Karlovac、クロアチア、47000
- Opca bolnica Karlovac
-
Krapinske Toplice、クロアチア、49217
- Specijalna bolnica Krapinske Toplice - Endokrinologija
-
Krapinske Toplice、クロアチア、49217
- Specijalna Bolnica za medicinsku rehabilitaciju Krapinske Toplice_Endocrinology
-
Osijek、クロアチア、31 000
- Klinicki bolnicki centar Osijek_Endocrinology
-
Osijek、クロアチア、31 000
- Klinicki bolnicki centar Osijek
-
Varaždin、クロアチア、42 000
- Opca bolnica Varazdin_Endocrinology
-
Varaždin、クロアチア、42 000
- Opca bolnica Varazdin
-
-
City of Zagreb
-
Zagreb、City of Zagreb、クロアチア、10000
- Poliklinika Solmed
-
-
Primorje-Gorski Kotar County
-
Rijeka、Primorje-Gorski Kotar County、クロアチア、51 000
- KBC Rijeka, Endokrinologija
-
Rijeka、Primorje-Gorski Kotar County、クロアチア、51 000
- Clinical Hospital Centre Rijeka_Endocrinology
-
-
-
-
-
A Coruña、スペイン、15006
- Complejo Hospitalario Universitario A Coruña
-
Barcelona、スペイン、08036
- Hospital Clinic i Provincial
-
Castilleja de la Cuesta、スペイン、41950
- Hospital Vithas Sevilla
-
Madrid、スペイン、28007
- Hospital Gregorio Marañón
-
Pontevedra、スペイン
- Complejo Hospitalario de Pontevedra - Hospital de Montecelo
-
Santander、スペイン、39008
- Hospital Universitario Marqués de Valdecilla
-
Seville、スペイン、41003
- Clínica Nuevas Tecnologías en Diabetes y Endocrinología
-
Seville、スペイン、41010
- Hospital Infanta Luisa
-
Seville、スペイン、41950
- Hospital Nisa Sevilla Aljarafe
-
Seville、スペイン、41010
- H. Infanta Luisa_Endocrino y Obesidad
-
-
-
-
-
Poprad、スロバキア、05801
- DENTAVIA s.r.o.
-
Prešov、スロバキア、080 01
- DIABETOL, s.r.o.
-
Rimavská Sobota、スロバキア、979 01
- OLIVER - MED s.r.o.
-
Žilina、スロバキア、010 01
- MEDIVASA, s.r.o., Diabetologicka ambulancia
-
-
Slovak Republic
-
Šahy、Slovak Republic、スロバキア、93601
- Peter Farkas MD, s.r.o.
-
-
-
-
-
Elsterwerda、ドイツ、04910
- Zentrum für klinische Studien Südbrandenburg GmbH
-
Elsterwerda、ドイツ、04910
- Zentrum fuer klinische Studien Suedbrandenburg GmbH
-
Essen、ドイツ、45136
- InnoDiab Forschung GmbH
-
Hamburg、ドイツ、22607
- Wendisch/Dahl Hamburg
-
Hamburg、ドイツ、22607
- Wendisch - Dahl Hamburg - DZHW
-
Münster、ドイツ、48145
- Institut für Diabetesforschung GmbH Münster - Dr. med. Rose
-
Oldenburg in Holstein、ドイツ、23758
- RED-Institut für medizinische Forschung und Fortbildung GmbH
-
-
-
-
-
Budapest、ハンガリー、1106
- Bajcsy-Zsilinszky Kórház
-
Budapest、ハンガリー、1134
- MH Egészségügyi Központ
-
Debrecen、ハンガリー、4031
- Debreceni Egyetem
-
Debrecen、ハンガリー、H-4031
- Debreceni Egyetem
-
Debrecen、ハンガリー、H-4032
- Debreceni Egyetem
-
Gyula、ハンガリー、5700
- Békés Megyei Központi Kórház
-
Kaposvár、ハンガリー、7400
- Somogy Vármegyei Kaposi Mór Oktató Kórház
-
Kaposvár、ハンガリー、H-7400
- Somogy Vármegyei Kaposi Mór Oktató Kórház
-
-
Hajdú-Bihar
-
Debrecen、Hajdú-Bihar、ハンガリー、4032
- Debreceni Egyetem
-
-
-
-
-
Kyustendil、ブルガリア、2500
- Individual Practice For Specialized Outpatient Medical Care Doctor Miglena Rizova Ltd.
-
Kyustendil、ブルガリア、2500
- IPSOMC Dr. Miglena Rizova Ltd.
-
Plovdiv、ブルガリア、4002
- DCC Sveti Georgi EOOD
-
Plovdiv、ブルガリア、4001
- UMHAT "Kaspela", Depart. Endocrinology and Metab. Diseases
-
Plovdiv、ブルガリア、4002
- Diagnostic-Consultative Centre "Sveti Georgi" Eood
-
Plovdiv、ブルガリア、4001
- UMHAT Kaspela EOOD, Endocrinology and Metabolic Diseases Clinic
-
Sofia、ブルガリア、1431
- USHATE "Akad. Ivan Penchev" Second Clinic of Endocrinology
-
Sofia、ブルガリア、1431
- UMHAT "Aleksandrovska"
-
Sofia、ブルガリア、1000
- Medical centre Regina Life Clinic EOOD
-
Sofia、ブルガリア、1431
- USHATE Akad. Ivan Penchev EAD, Second Clinic of Endocrinology
-
Sofia、ブルガリア、1431
- UMHAT Aleksandrovska EAD, Densitometry and Bone Metabolic Diseases
-
Varna、ブルガリア、9020
- AIPSMC Dr. Artin Magardichyan EOOD
-
-
-
-
-
Bialystok、ポーランド、15-375
- Specderm Poznańska Spółka Jawna
-
Lublin、ポーランド、20-718
- EKAMED sp. z o.o.
-
Ruda Śląska、ポーランド、41-709
- Niepubliczny Zaklad Opieki Zdrowotnej Przychodnia Specjalistyczna A Wittek H Rudzki Sp. j.
-
Warsaw、ポーランド、02-507
- PANSTWOWY INSTYTUT MEDYCZNY MSWiA
-
-
Gornoslaskie
-
Ruda Śląska、Gornoslaskie、ポーランド、41-709
- Niepubliczny Zaklad Opieki Zdrowotnej Przychodnia Specjalistyczna A Wittek H Rudzki Sp. j.
-
-
Lesser Poland Voivodeship
-
Krakow、Lesser Poland Voivodeship、ポーランド、31-261
- Med. Cent. Diabet. Endo. Metabol. DIAB-ENDO-MET
-
Oświęcim、Lesser Poland Voivodeship、ポーランド、32-600
- Formed 2 Sp. z o.o.
-
-
Lower Silesian Voivodeship
-
Legnica、Lower Silesian Voivodeship、ポーランド、59-220
- Beata Mikłaszewicz & Dariusz Dąbrowski "CARDIAMED" s.j.
-
Legnica、Lower Silesian Voivodeship、ポーランド、59-220
- Beata Miklaszewicz & Dariusz Dabrowski "CARDIAMED" s.j.
-
-
Lublin Voivodeship
-
Lublin、Lublin Voivodeship、ポーランド、20-718
- EKAMED sp. z o.o.
-
-
Masovian Voivodeship
-
Siedlce、Masovian Voivodeship、ポーランド、08-110
- ETG Siedlce
-
-
Podlaskie Voivodeship
-
Bialystok、Podlaskie Voivodeship、ポーランド、15-879
- NZOZ Vita-Diabetica Malgorzata Buraczyk
-
Bialystok、Podlaskie Voivodeship、ポーランド、15-375
- Specderm Poznanska Sp. j.
-
-
Łódź Voivodeship
-
Lodz、Łódź Voivodeship、ポーランド、90-302
- Santa Sp. z o.o, Santa Familia Centrum Badan, Profilaktyki i Leczenia
-
-
-
-
-
Brasov、ルーマニア、500101
- Mariodiab Clinic SRL
-
Timișoara、ルーマニア、300723
- Spitalul Clinic Judetean De Urgenta Pius Brinzeu Timisoara
-
Timișoara、ルーマニア、300288
- Cabinet Medical Dr Geru SRL
-
-
Bihor County
-
Oradea、Bihor County、ルーマニア、410025
- SC Grand Med SRL
-
Oradea、Bihor County、ルーマニア、410159
- Grandmed SRL
-
-
Bucharest
-
Bucharest、Bucharest、ルーマニア、020475
- Institutul National De Diabet Nutritie Si Boli Metabolice Prof.Dr.N.Paulescu Bucuresti- Ion Movila
-
-
Bucurestii
-
Bucharest、Bucurestii、ルーマニア、020475
- Institutul National De Diabet Nutritie Si Boli Metabolice Prof.Dr.N.Paulescu Bucuresti- Ion Movila
-
-
Cluj
-
Cluj-Napoca、Cluj、ルーマニア、400006
- Spitalul Clinic Judetean Urgenta Cluj-Napoca
-
-
Mureș County
-
Târgu Mureş、Mureș County、ルーマニア、540142
- Sc Mediab Srl
-
-
Prahova
-
Ploieşti、Prahova、ルーマニア、100018
- Novus Medical Clinica SRL
-
-
-
-
-
Aichi、日本、468-0009
- TOSAKI Clinic for Diabetes and Endocrinology_Diabetes and Endocrinology
-
Chiba、日本、261-0004
- Tokuyama clinic_Diabetic internal medicine
-
Chiba、日本、261-0004
- Tokuyama clinic
-
Chiba-shi, Chiba、日本、260-0804
- Akaicho Clinic
-
Ibaraki、日本、311-0113
- Naka Kinen Clinic
-
Ibaraki、日本、311-0113
- Naka Kinen Clinic_Internal medicine
-
Tokyo、日本、103-0027
- Tokyo-Eki Center-building Clinic
-
Tokyo、日本、104-0031
- Fukuwa Clinic
-
Tokyo、日本、103-0027
- Tokyo-Eki Center-building Clinic_Internal Medicine
-
Tokyo、日本、104-0031
- Fukuwa Clinic_Internal Medicine
-
-
Miyazaki
-
Miyazaki、Miyazaki、日本、880-0034
- Heiwadai Hospital_Internal Medicine
-
Miyazaki、Miyazaki、日本、880-0034
- Heiwadai Hospital
-
-
参加基準
適格基準
就学可能な年齢
健康ボランティアの受け入れ
受講資格のある性別
説明
Inclusion Criteria:
- Male or female, aged 18-75 years (both inclusive) at the time of signing the informed consent.
- Diagnosed with type 2 diabetes mellitus greater or equal to 180 days before screening.
- Stable daily dose(s) greater or equal to 90 days before screening of the following antidiabetic drug(s) or combination regimen(s) at effective or maximum tolerated dose as judged by the investigator: metformin with or without SGLT2 inhibitor.
- HbA1c of 7.0-10.0 procent (53-86 mmol/mol) (both inclusive) as assessed by central laboratory at screening.
- Body mass index between greater or equal to 23.0 and below 50.0 kg/m^2.
- Able and willing to adhere to the protocol including wearing a continuous glucose monitoring (CGM) device provided for the study, as judged by the investigator.
Exclusion Criteria:
- Treatment with any medication for the indication of diabetes or obesity other than stated in the inclusion criteria within 90 days before screening. However, short term insulin treatment for a maximum of 14 consecutive days and prior insulin treatment for gestational diabetes are allowed.
- Uncontrolled and potentially unstable diabetic retinopathy or maculopathy. Verified by a fundus examination performed within 90 days before screening or in the period between screening and randomisation. Pharmacological pupil-dilation is a requirement unless using a digital fundus photography camera specified for non-dilated examination.
- Known hypoglycaemic unawareness as indicated by the investigator according to Clarke's questionnaire question.
研究計画
研究はどのように設計されていますか?
デザインの詳細
- 主な目的:処理
- 割り当て:ランダム化
- 介入モデル:並列代入
- マスキング:4倍
武器と介入
参加者グループ / アーム |
介入・治療 |
|---|---|
|
プラセボコンパレーター:Placebo subcutaneous
Placebo for subcutaneous treatment |
NNC0487-0111 placebo administered subcutanously (under the skin) |
|
実験的:NNC0487-0111 subcutaneous dose 1
NNC0487-0111 subcutaneous dose 1 treatment |
NNC0487-0111 administered subcutanously (under the skin) |
|
実験的:NNC0487-0111 subcutaneous dose 2
NNC0487-0111 subcutaneous dose 2 treatment |
NNC0487-0111 administered subcutanously (under the skin) |
|
実験的:NNC0487-0111 subcutaneous dose 3
NNC0487-0111 subcutaneous dose 3 treatment |
NNC0487-0111 administered subcutanously (under the skin) |
|
実験的:NNC0487-0111 subcutaneous dose 4
NNC0487-0111 subcutaneous dose 4 treatment |
NNC0487-0111 administered subcutanously (under the skin) |
|
実験的:NNC0487-0111 subcutaneous dose 5
NNC0487-0111 subcutaneous dose 5 treatment |
NNC0487-0111 administered subcutanously (under the skin) |
|
実験的:NNC0487-0111 subcutaneous dose 6
NNC0487-0111 subcutaneous dose 6 treatment |
NNC0487-0111 administered subcutanously (under the skin) |
|
プラセボコンパレーター:Placebo oral
Placebo for oral treatment |
NNC0487-0111 placebo administered orally (in the mouth) |
|
実験的:NNC0487-0111 oral dose 1
NNC0487-0111 oral dose 1 treatment |
NNC0487-0111 administered orally (in the mouth) |
|
実験的:NNC0487-0111 oral dose 2
NNC0487-0111 oral dose 2 treatment |
NNC0487-0111 administered orally (in the mouth) |
|
実験的:NNC0487-0111 oral dose 3
NNC0487-0111 oral dose 3 treatment |
NNC0487-0111 administered orally (in the mouth) |
この研究は何を測定していますか?
主要な結果の測定
結果測定 |
メジャーの説明 |
時間枠 |
|---|---|---|
|
Change in HbA1c
時間枠:From baseline (week 0) to end of treatment (week 36)
|
percent point |
From baseline (week 0) to end of treatment (week 36)
|
二次結果の測定
結果測定 |
メジャーの説明 |
時間枠 |
|---|---|---|
|
Relative change in body weight
時間枠:From baseline (week 0) to end of treatment (week 36)
|
percent |
From baseline (week 0) to end of treatment (week 36)
|
|
Change in body weight
時間枠:From baseline (week 0) to end of treatment (week 36)
|
kg |
From baseline (week 0) to end of treatment (week 36)
|
|
Change in fasting plasma glucose (FPG)
時間枠:From baseline (week 0) to end of treatment (week 36)
|
mmol/L |
From baseline (week 0) to end of treatment (week 36)
|
|
CGM: Change in time in range (TIR) 3.9-10.0 mmol/L (70-180 mg/dL)
時間枠:From baseline (week 0) to end of treatment (week 36)
|
percent points |
From baseline (week 0) to end of treatment (week 36)
|
|
Change in body mass index (BMI)
時間枠:From baseline (week 0) to end of treatment (week 36)
|
kg/m^2 |
From baseline (week 0) to end of treatment (week 36)
|
|
Change in waist circumference
時間枠:From baseline (week 0) to end of treatment (week 36)
|
cm |
From baseline (week 0) to end of treatment (week 36)
|
|
Change in systolic blood pressure (SBP)
時間枠:From baseline (week 0) to end of treatment (week 36)
|
mmHg |
From baseline (week 0) to end of treatment (week 36)
|
|
Change in average 24-hour systolic blood pressure (SBP)
時間枠:From baseline (week 0) to end of treatment (week 36)
|
mmHg |
From baseline (week 0) to end of treatment (week 36)
|
|
Change in high sensitivity C-Reactive Protein (hsCRP)
時間枠:From baseline (week 0) to end of treatment (week 36)
|
Ratio to baseline |
From baseline (week 0) to end of treatment (week 36)
|
|
Change in total cholesterol
時間枠:From baseline (week 0) to end of treatment (week 36)
|
Ratio to baseline |
From baseline (week 0) to end of treatment (week 36)
|
|
Change in high-density lipoprotein (HDL) cholesterol
時間枠:From baseline (week 0) to end of treatment (week 36)
|
Ratio to baseline |
From baseline (week 0) to end of treatment (week 36)
|
|
Change in low-density lipoprotein (LDL) cholesterol
時間枠:From baseline (week 0) to end of treatment (week 36)
|
Ratio to baseline |
From baseline (week 0) to end of treatment (week 36)
|
|
Change in triglycerides
時間枠:From baseline (week 0) to end of treatment (week 36)
|
Ratio to baseline |
From baseline (week 0) to end of treatment (week 36)
|
|
Number of adverse events
時間枠:From baseline (week 0) to end of study (week 40)
|
Count of events |
From baseline (week 0) to end of study (week 40)
|
|
Change in Urinary Albumin/Creatinine Ratio (UACR)
時間枠:From baseline (week 0) to end of treatment (week 36)
|
Ratio to baseline |
From baseline (week 0) to end of treatment (week 36)
|
|
Participant without macroalbuminuria (UACR < 300 mg/g) at baseline (week 0) developing (yes/no) new onset of macroalbuminuria (UACR ≥ 300 mg/g)
時間枠:At end of treatment (week 36)
|
Count of participant |
At end of treatment (week 36)
|
|
Change in eGFR creatinine- and cystatin C based CKD-EPI
時間枠:From baseline (week 0) to end of treatment (week 36)
|
mL/min/1.73 m^2 |
From baseline (week 0) to end of treatment (week 36)
|
協力者と研究者
スポンサー
捜査官
- スタディディレクター:Clinical Transparency (dept. 2834)、Novo Nordisk A/S
出版物と役立つリンク
一般刊行物
- Mora P, Aroda VR, Asong M, Bluher M, Heftdal LD, Carlander AF, Vilsen LN, Rosenstock J. Efficacy and safety of once-weekly subcutaneous zenagamtide, a novel unimolecular GLP-1 and amylin receptor agonist, in type 2 diabetes: a multicentre, randomised, parallel, double-blind, placebo-controlled, dose-finding, phase 2 trial. Lancet. 2026 Jul 30:S0140-6736(26)01248-1. doi: 10.1016/S0140-6736(26)01248-1. Online ahead of print.
- Mora P, Aroda VR, Asong M, Bluher M, Carlander AF, Kaltoft M, Vilsen LN, Rosenstock J. Efficacy and safety of once-daily oral zenagamtide, a novel unimolecular GLP-1 and amylin receptor agonist, in adults with type 2 diabetes: a multicentre, randomised, parallel, double-blind, placebo-controlled, dose-finding, phase 2 trial. Lancet. 2026 Jul 30:S0140-6736(26)01247-X. doi: 10.1016/S0140-6736(26)01247-X. Online ahead of print.
研究記録日
主要日程の研究
研究開始 (実際)
一次修了 (実際)
研究の完了 (実際)
試験登録日
最初に提出
QC基準を満たした最初の提出物
最初の投稿 (実際)
学習記録の更新
投稿された最後の更新 (実際)
QC基準を満たした最後の更新が送信されました
最終確認日
詳しくは
本研究に関する用語
その他の研究ID番号
- NN9490-7678
- U1111-1296-9708 (その他の識別子:World Health Organization (WHO))
- 2023-509412-28 (その他の識別子:European Medical Agency (EMA))
- 2023 (米国 NIH グラント/契約)
個々の参加者データ (IPD) の計画
個々の参加者データ (IPD) を共有する予定はありますか?
IPD プランの説明
According to the Novo Nordisk disclosure commitment on novonordisk-trials.com
医薬品およびデバイス情報、研究文書
米国FDA規制医薬品の研究
米国FDA規制機器製品の研究
この情報は、Web サイト clinicaltrials.gov から変更なしで直接取得したものです。研究の詳細を変更、削除、または更新するリクエストがある場合は、register@clinicaltrials.gov。 までご連絡ください。 clinicaltrials.gov に変更が加えられるとすぐに、ウェブサイトでも自動的に更新されます。